Table 2.
Genotype distributions of ADH2 and ALDH2 polymorphisms and their impact on risk of head and neck cancer
| Cases | Controls † | Model 1 ‡ | Model 2 ‡ | |||||
|---|---|---|---|---|---|---|---|---|
| n | % | n | % | OR | 95% CI | OR | 95% CI | |
| ADH2 | ||||||||
| His/His | 138 | 57.7 | 471 | 65.8 | 1.00 | Reference | 1.00 | Reference |
| His/Arg | 75 | 31.4 | 213 | 30.0 | 1.21 | 0.87–1.68 | 1.17 | 0.83–1.63 |
| Arg/Arg | 26 | 10.9 | 31 | 4.3 | 2.88 | 1.65–5.01 | 2.67 | 1.51–4.75 |
| P‐trend = 0.001 | P‐trend = 0.004 | |||||||
| ALDH2 | ||||||||
| Glu/Glu | 108 | 45.2 | 356 | 49.8 | 1.00 | Reference | 1.00 | Reference |
| Glu/Lys | 120 | 50.2 | 302 | 42.2 | 1.33 | 0.98–1.80 | 1.66 | 1.20–2.31 |
| Lys/Lys | 11 | 4.6 | 57 | 8.0 | 0.64 | 0.32–1.26 | 1.43 | 0.68–3.01 |
| P‐trend = 0.765 | P‐trend = 0.01 | |||||||
†
One control was excluded from the analysis because ADH2/ALDH2 genotypes could not be defined.
‡
‡ Model 1 adjusted for age and sex; model 2 adjusted for age, sex, drinking and smoking. CI, confidence interval; OR, odds ratio.